Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.65 |
| ▸ | CTSS | P25774 | 7/20 | 0.65 |
| ▸ | CTSL | P07711 | 2/20 | 0.65 |
| ▸ | CTSB | P07858 | 1/20 | 0.65 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.60 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.42 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13764937 | 0.88 | CTSS (0.72) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL18414075 | 0.88 | CTSS (0.72) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL5556517 | 0.86 | CTSS (0.68) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL24741085 | 0.85 | CAPN1 (0.74) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL7358427 | 0.83 | CAPN1 (0.70) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL10871974 | 0.83 | REN (0.51) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL10871989 | 0.83 | REN (0.51) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL15220307 | 0.82 | KMT2A (0.51) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL1026995 | 0.82 | CTSS (0.60) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL17019827 | 0.82 | MEN1 (0.46) | CTSKCTSSCTSLCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143375-B2 | Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-03-27 | — | — | US | disclosed |
| US-8143375-B2 | Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-03-27 | — | — | US | disclosed |
| US-20100317832-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | ZEALAND PHARMA A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| US-20100317832-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | ZEALAND PHARMA A/S (DK) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317832-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | QDPR, VIP, AAAS | CTSK 2282/4885CTSS 2196/4885CTSL 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.